

K63 TUBE (FLAG)

Cat. # UM604

Background

K63-linked polyubiquitin can serve as a marker of autophagy and DNA repair. FLAG® K63 TUBE is an ideal reagent for efficient isolation and enrichment of K63-polyubiquitinated proteins from cell and tissue extracts or in vitro synthesized mixtures. FLAG® K63 TUBE consists of multiple ubiquitin interaction motifs (UIMs) joined by a rigid, helical linker that spaces the UIMs for selective binding to extended K63-linked polyubiquitin chains. The result is a peptide that exhibits high affinity binding to K63-linked polyubiquitin together with 1000 to 10,000-fold selectivity over K48- and K11- linkages. Expression of this peptide in vivo inhibits K63-linked polyubiquitin-dependent processes and protects K63-linked polyubiquitin chains from degradation. Combining this peptide with a FLAG epitope tag generates, for the first time, a powerful affinity reagent suitable for isolation, purification and characterization of proteins modified by K63-linked polyubiquitin. Flag K63-TUBE allows isolation of K63-linked polyubiquitin without the need for overexpression of ubiquitin mutants, tagged-ubiquitin or the inclusion of DUB inhibitors any of which could alter cellular physiology. (FLAG is a registered trademark of Sigma-Aldrich Corporation LLC).


Application(s)

- Isolation and enrichment of K63-linked polyubiquitinated proteins from cell and tissue extracts
- Isolation of ubiquitinated proteins for proteomic studies (e.g., mass spectrometry)
- Far-western blot analysis of K63-ubiquitinated proteins

Product Specifications

Affinity Tag	Flag
Purity	> 95% by RP-HPLC
Molecular Weight	22 kDa
Quantity	50 µg
Expression System	<i>E. Coli</i>
Physical State	Liquid
Buffer	PBS, pH 7.2
Concentration	Variable, depending on lot number
Storage	Store at -80° C. Avoid repeated freeze/thaw cycles

Product QC



All products are for research use only • Not intended for human or animal diagnostic or therapeutic uses
Copyright © 2025 LifeSensors, Inc. All Rights Reserved

K63 TUBE (FLAG)

Cat. # UM604

References

1. Wang, Y. T., Liu, T. Y., Shen, C. H., Lin, S. Y., Hung, C. C., Hsu, L. C., & Chen, G. C. (2022). K48/K63-linked polyubiquitination of ATG9A by TRAF6 E3 ligase regulates oxidative stress-induced autophagy. *Cell reports*, 38(8), 110354.
2. Gross, P. H., Sheets, K. J., Warren, N. A., Ghosh, S., Varghese, R. E., Wass, K. E., & Kadimisetty, K. (2022). Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation. *Biochemical and biophysical research communications*, 628, 68–75.
3. M. Mattern, J. Sutherland, K. Kadimisetty, R. Barrio, M.S. Rodriguez (2019). Using ubiquitin binders to decipher the ubiquitin code. *Trends Biochem. Sci.*, 44, pp. 599-615
4. Messick, T. E., and Greenberg, R. A. (2009) The ubiquitin landscape at DNA double-strand breaks, *J Cell Biol* 187, 319-326.
5. Olzman, J. A., and Chin, L. S. (2008) Parkin-mediated K63-linked polyubiquitination. A signal for targeting misfolded proteins to the aggresome-autophagy pathway, *Autophagy* 4, 85-87.
6. Lim, K. L., and Lim, G. G. (2011) k63-linked ubiquitination and neurodegeneration, *Neurobiol Dis* 43, 9-16.
7. Hjerpe, R., Aillet, F., Lopitz-Otsoa, F., Lang, V., England, P., and Rodriguez, M. S. (2009) Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities, *EMBO Rep* 10, 1250-1258.
8. Sims, J. J., Scavone, F., Cooper, E. M., Kane, L. A., Youle, R. J., Boeke, J. D., and Cohen, R. E. (2012) Polyubiquitin sensor proteins reveal localization and linkage-type dependence of cellular ubiquitin signaling, *Nat Meth* 9, 303-309.
9. Shaik, S., Kumar Reddy Gayam, P., Chaudhary, M., Singh, G., & Pai, A. (2024). Advances in designing ternary complexes: Integrating in-silico and biochemical methods for PROTAC optimisation in target protein degradation. *Bioorganic Chemistry*, 153(107868), 107868.
10. Welsh, C. L., Allen, S., & Madan, L. K. (2023). Setting sail: Maneuvering SHP2 activity and its effects in cancer. In *Advances in Cancer Research*. *Advances in Cancer Research* 160, 17–60.
11. Zhao, X., Chen, Y., Su, H., & Zhang, L. (2023). From classic medicinal chemistry to state-of-the-art interdisciplinary medicine: Recent advances in proteolysis-targeting chimeras technology. *Interdisciplinary Medicine*, 1(2), e20230004.

All products are for research use only • Not intended for human or animal diagnostic or therapeutic uses
Copyright © 2025 LifeSensors, Inc. All Rights Reserved